Jaxteran

Dimethyl fumarate, the active ingredient in Jaxteran, is an immunomodulating agent presented as an oral formulation for oral use. It is used as a disease-modifying therapy in adults with multiple sclerosis and as a systemic treatment for moderate to severe psoriasis.

GNH USA supplies Jaxteran as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable sourcing for regulated markets. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Jaxteran (dimethyl fumarate) is an oral immunomodulating agent that acts on the Nrf2 pathway and is indicated for disease-modifying therapy in the following conditions:

Multiple sclerosis: reduces annual relapse rate and delays progression of disability in adult patients. Relapsing‑remitting multiple sclerosis: decreases inflammatory lesions in the central nervous system and improves MRI outcomes. Psoriasis: provides systemic control of plaque formation and reduces skin scaling in moderate to severe disease. Active disease multiple sclerosis: improves patient-reported outcomes and quality of life.

Common Side Effects: - Flushing: transient warmth and redness, often mild. - Gastrointestinal upset: nausea, abdominal pain, or diarrhea. - Lymphopenia: reduced lymphocyte count, usually mild. - Headache: occasional mild to moderate pain. - Nausea: feeling of sickness without vomiting.

Serious or Rare Side Effects: - Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal brain infection. - Severe lymphopenia: markedly low lymphocyte levels increasing infection risk. - Hepatic injury: elevated liver enzymes or hepatitis. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Stevens‑Johnson syndrome: rare severe skin reaction.

Before initiating therapy, clinicians should consider several safety measures.

Monitor lymphocyte counts: baseline and periodic testing recommended. Assess hepatic function: check liver enzymes before initiation. Avoid in patients with active infection: defer treatment until resolved. Pregnancy and breastfeeding: use only if potential benefit outweighs risk. Vaccinations: administer required vaccines before starting therapy. Store at ambient temperature: keep below 25°C, protect from moisture and light.

Dimethyl fumarate may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Live vaccines: contraindicated during treatment. - Immunosuppressants: may increase risk of severe infection. - Drugs causing lymphopenia: avoid concurrent use.

Moderate Interactions (Monitor Closely): - Antiepileptic drugs: may alter plasma levels. - Statins: potential increased risk of muscle toxicity. - Warfarin: monitor INR closely for anticoagulation changes.